MovDisordV3, Main, Exploration, bibRecord, 003747

Retrospective evaluation of the dose of dysport and BOTOX in the management of cervical dystonia and blepharospasm: The REAL DOSE study

Identifieur interne : 003747 ( Main/Exploration ); précédent : 003746; suivant : 003748

Retrospective evaluation of the dose of dysport and BOTOX in the management of cervical dystonia and blepharospasm: The REAL DOSE study

Auteurs : Albert Marchetti [États-Unis] ; Raf Magar [États-Unis] ; Leslie Findley [Royaume-Uni] ; Jan P. Larsen [Norvège] ; Zvezdan Pirtosek [Slovénie] ; Evzen R Užižka [République tchèque] ; Robert Jech [République tchèque] ; Jaroslaw Sławek [Pologne] ; Fayyaz Ahmed [Royaume-Uni]

Source :

Movement Disorders [ 0885-3185 ] ; 2005-08.

RBID : ISTEX:E157C5AC16E873F5B278A64D8217108550AB8135

Descripteurs français

Pascal (Inist)
- Blépharospasme, Bontoxilysin, Complication, Conduite à tenir, Dystonie, Evaluation, Rétrospective, Système nerveux pathologie.

English descriptors

KwdEn :
- Adult, Aged, Blepharospasm, Blepharospasm (drug therapy), Bontoxilysin, Botulinum Toxins, Type A (administration & dosage), Botulinum Toxins, Type A (therapeutic use), Clinical management, Complication, Dose-Response Relationship, Drug, Dystonia, Europe (epidemiology), Evaluation, Female, Follow-Up Studies, Humans, Male, Middle Aged, Nervous system diseases, Neuromuscular Agents (administration & dosage), Neuromuscular Agents (therapeutic use), Retrospective, Retrospective Studies, Severity of Illness Index, Time Factors, Torticollis (drug therapy), Treatment Outcome, adverse events, blepharospasm, botulinum toxin type A, cervical dystonia, dose ratio.
MESH :
- chemical , administration & dosage : Botulinum Toxins, Type A, Neuromuscular Agents.
- geographic , epidemiology : Europe.
- drug therapy : Blepharospasm, Torticollis.
- chemical , therapeutic use : Botulinum Toxins, Type A, Neuromuscular Agents.
- Adult, Aged, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Humans, Male, Middle Aged, Retrospective Studies, Severity of Illness Index, Time Factors, Treatment Outcome.

Abstract

The purpose of this study is to evaluate the real‐world dose utilization of Dysport and BOTOX for cervical dystonia and blepharospasm. Six investigational sites (five countries) were identified. Investigators abstracted utilization data for patients who received Dysport before switching to BOTOX or BOTOX before switching to Dysport. Patients were identified during scheduled clinic visits and selected if they met study criteria, which included treatment for at least 2 consecutive years (at least 1 year with Dysport or BOTOX, then switched and maintained on BOTOX or Dysport for at least another year). A total of 114 patients were included in the assessment. Ratios of mean dose for Dysport to BOTOX ranged from a low of 2:1 to a high of 11:1. Thirty‐one percent of patients fell into the Dysport‐to‐BOTOX ratio grouping of 5:1 to less than 6:1; 30% of patients had a mean ratio of Dysport to BOTOX of 4:1 to less than 5:1; and only 21% of all patients evaluated fell into the Dysport‐to‐BOTOX ratio grouping of 3:1 to less than 4:1. Results are consistent with United Kingdom labeling for botulinum toxins stating that units of different serotype A toxins are not interchangeable and simple dose‐conversion factors are not applicable. © 2005 Movement Disorder Society

Url:

DOI: 10.1002/mds.20468

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Retrospective evaluation of the dose of dysport and BOTOX in the management of cervical dystonia and blepharospasm: The REAL DOSE study</title>
<author><name sortKey="Marchetti, Albert" sort="Marchetti, Albert" uniqKey="Marchetti A" first="Albert" last="Marchetti">Albert Marchetti</name>
</author>
<author><name sortKey="Magar, Raf" sort="Magar, Raf" uniqKey="Magar R" first="Raf" last="Magar">Raf Magar</name>
</author>
<author><name sortKey="Findley, Leslie" sort="Findley, Leslie" uniqKey="Findley L" first="Leslie" last="Findley">Leslie Findley</name>
</author>
<author><name sortKey="Larsen, Jan P" sort="Larsen, Jan P" uniqKey="Larsen J" first="Jan P." last="Larsen">Jan P. Larsen</name>
</author>
<author><name sortKey="Pirtosek, Zvezdan" sort="Pirtosek, Zvezdan" uniqKey="Pirtosek Z" first="Zvezdan" last="Pirtosek">Zvezdan Pirtosek</name>
</author>
<author><name sortKey="R Uzizka, Evzen" sort="R Uzizka, Evzen" uniqKey="R Uzizka E" first="Evzen" last="R Užižka">Evzen R Užižka</name>
</author>
<author><name sortKey="Jech, Robert" sort="Jech, Robert" uniqKey="Jech R" first="Robert" last="Jech">Robert Jech</name>
</author>
<author><name sortKey="Slawek, Jaroslaw" sort="Slawek, Jaroslaw" uniqKey="Slawek J" first="Jaroslaw" last="Sławek">Jaroslaw Sławek</name>
</author>
<author><name sortKey="Ahmed, Fayyaz" sort="Ahmed, Fayyaz" uniqKey="Ahmed F" first="Fayyaz" last="Ahmed">Fayyaz Ahmed</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:E157C5AC16E873F5B278A64D8217108550AB8135</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1002/mds.20468</idno>
<idno type="url">https://api.istex.fr/document/E157C5AC16E873F5B278A64D8217108550AB8135/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001076</idno>
<idno type="wicri:Area/Istex/Curation">001076</idno>
<idno type="wicri:Area/Istex/Checkpoint">002154</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Marchetti A:retrospective:evaluation:of</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15810022</idno>
<idno type="wicri:Area/PubMed/Corpus">003085</idno>
<idno type="wicri:Area/PubMed/Curation">003085</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002F78</idno>
<idno type="wicri:Area/Ncbi/Merge">001216</idno>
<idno type="wicri:Area/Ncbi/Curation">001216</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001216</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Marchetti A:retrospective:evaluation:of</idno>
<idno type="wicri:Area/Main/Merge">004E31</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:05-0444020</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001E13</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000F08</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001D27</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Marchetti A:retrospective:evaluation:of</idno>
<idno type="wicri:Area/Main/Merge">005205</idno>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:7E959413EE7825757347FE6145C39C5DCF45A735</idno>
<idno type="url">https://api.istex.fr/document/7E959413EE7825757347FE6145C39C5DCF45A735/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">004267</idno>
<idno type="wicri:Area/Istex/Curation">004267</idno>
<idno type="wicri:Area/Istex/Checkpoint">002153</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Marchetti A:retrospective:evaluation:of</idno>
<idno type="wicri:Area/Main/Merge">004E30</idno>
<idno type="wicri:Area/Main/Curation">003747</idno>
<idno type="wicri:Area/Main/Exploration">003747</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Retrospective evaluation of the dose of dysport and BOTOX in the management of cervical dystonia and blepharospasm: The REAL DOSE study</title>
<author><name sortKey="Marchetti, Albert" sort="Marchetti, Albert" uniqKey="Marchetti A" first="Albert" last="Marchetti">Albert Marchetti</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Thomson Health Economics Research, Secaucus, New Jersey</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Magar, Raf" sort="Magar, Raf" uniqKey="Magar R" first="Raf" last="Magar">Raf Magar</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Thomson Health Economics Research, Secaucus, New Jersey</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Findley, Leslie" sort="Findley, Leslie" uniqKey="Findley L" first="Leslie" last="Findley">Leslie Findley</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Essex Neuroscience Unit, Romford</wicri:regionArea>
<wicri:noRegion>Romford</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Larsen, Jan P" sort="Larsen, Jan P" uniqKey="Larsen J" first="Jan P." last="Larsen">Jan P. Larsen</name>
<affiliation wicri:level="1"><country xml:lang="fr">Norvège</country>
<wicri:regionArea>Central Hospital of Rogaland, Stavanger</wicri:regionArea>
<wicri:noRegion>Stavanger</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pirtosek, Zvezdan" sort="Pirtosek, Zvezdan" uniqKey="Pirtosek Z" first="Zvezdan" last="Pirtosek">Zvezdan Pirtosek</name>
<affiliation wicri:level="1"><country xml:lang="fr">Slovénie</country>
<wicri:regionArea>University Clinical Centre, Ljubljana</wicri:regionArea>
<wicri:noRegion>Ljubljana</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="R Uzizka, Evzen" sort="R Uzizka, Evzen" uniqKey="R Uzizka E" first="Evzen" last="R Užižka">Evzen R Užižka</name>
<affiliation wicri:level="3"><country xml:lang="fr">République tchèque</country>
<wicri:regionArea>Charles University, Prague</wicri:regionArea>
<placeName><settlement type="city">Prague</settlement>
<region type="région" nuts="2">Bohême centrale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jech, Robert" sort="Jech, Robert" uniqKey="Jech R" first="Robert" last="Jech">Robert Jech</name>
<affiliation wicri:level="3"><country xml:lang="fr">République tchèque</country>
<wicri:regionArea>Charles University, Prague</wicri:regionArea>
<placeName><settlement type="city">Prague</settlement>
<region type="région" nuts="2">Bohême centrale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Slawek, Jaroslaw" sort="Slawek, Jaroslaw" uniqKey="Slawek J" first="Jaroslaw" last="Sławek">Jaroslaw Sławek</name>
<affiliation wicri:level="1"><country xml:lang="fr">Pologne</country>
<wicri:regionArea>St. Adalbert Hospital, Gdansk</wicri:regionArea>
<wicri:noRegion>Gdansk</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ahmed, Fayyaz" sort="Ahmed, Fayyaz" uniqKey="Ahmed F" first="Fayyaz" last="Ahmed">Fayyaz Ahmed</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Hull Royal Infirmary, Hull</wicri:regionArea>
<wicri:noRegion>Hull</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2005-08">2005-08</date>
<biblScope unit="vol">20</biblScope>
<biblScope unit="issue">8</biblScope>
<biblScope unit="page" from="937">937</biblScope>
<biblScope unit="page" to="944">944</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">E157C5AC16E873F5B278A64D8217108550AB8135</idno>
<idno type="DOI">10.1002/mds.20468</idno>
<idno type="ArticleID">MDS20468</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Blepharospasm</term>
<term>Blepharospasm (drug therapy)</term>
<term>Bontoxilysin</term>
<term>Botulinum Toxins, Type A (administration & dosage)</term>
<term>Botulinum Toxins, Type A (therapeutic use)</term>
<term>Clinical management</term>
<term>Complication</term>
<term>Dose-Response Relationship, Drug</term>
<term>Dystonia</term>
<term>Europe (epidemiology)</term>
<term>Evaluation</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Neuromuscular Agents (administration & dosage)</term>
<term>Neuromuscular Agents (therapeutic use)</term>
<term>Retrospective</term>
<term>Retrospective Studies</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
<term>Torticollis (drug therapy)</term>
<term>Treatment Outcome</term>
<term>adverse events</term>
<term>blepharospasm</term>
<term>botulinum toxin type A</term>
<term>cervical dystonia</term>
<term>dose ratio</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Botulinum Toxins, Type A</term>
<term>Neuromuscular Agents</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Europe</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Blepharospasm</term>
<term>Torticollis</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins, Type A</term>
<term>Neuromuscular Agents</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Dose-Response Relationship, Drug</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Retrospective Studies</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Blépharospasme</term>
<term>Bontoxilysin</term>
<term>Complication</term>
<term>Conduite à tenir</term>
<term>Dystonie</term>
<term>Evaluation</term>
<term>Rétrospective</term>
<term>Système nerveux pathologie</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The purpose of this study is to evaluate the real‐world dose utilization of Dysport and BOTOX for cervical dystonia and blepharospasm. Six investigational sites (five countries) were identified. Investigators abstracted utilization data for patients who received Dysport before switching to BOTOX or BOTOX before switching to Dysport. Patients were identified during scheduled clinic visits and selected if they met study criteria, which included treatment for at least 2 consecutive years (at least 1 year with Dysport or BOTOX, then switched and maintained on BOTOX or Dysport for at least another year). A total of 114 patients were included in the assessment. Ratios of mean dose for Dysport to BOTOX ranged from a low of 2:1 to a high of 11:1. Thirty‐one percent of patients fell into the Dysport‐to‐BOTOX ratio grouping of 5:1 to less than 6:1; 30% of patients had a mean ratio of Dysport to BOTOX of 4:1 to less than 5:1; and only 21% of all patients evaluated fell into the Dysport‐to‐BOTOX ratio grouping of 3:1 to less than 4:1. Results are consistent with United Kingdom labeling for botulinum toxins stating that units of different serotype A toxins are not interchangeable and simple dose‐conversion factors are not applicable. © 2005 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Norvège</li>
<li>Pologne</li>
<li>Royaume-Uni</li>
<li>République tchèque</li>
<li>Slovénie</li>
<li>États-Unis</li>
</country>
<region><li>Bohême centrale</li>
<li>New Jersey</li>
</region>
<settlement><li>Prague</li>
</settlement>
</list>
<tree><country name="États-Unis"><region name="New Jersey"><name sortKey="Marchetti, Albert" sort="Marchetti, Albert" uniqKey="Marchetti A" first="Albert" last="Marchetti">Albert Marchetti</name>
</region>
<name sortKey="Magar, Raf" sort="Magar, Raf" uniqKey="Magar R" first="Raf" last="Magar">Raf Magar</name>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Findley, Leslie" sort="Findley, Leslie" uniqKey="Findley L" first="Leslie" last="Findley">Leslie Findley</name>
</noRegion>
<name sortKey="Ahmed, Fayyaz" sort="Ahmed, Fayyaz" uniqKey="Ahmed F" first="Fayyaz" last="Ahmed">Fayyaz Ahmed</name>
</country>
<country name="Norvège"><noRegion><name sortKey="Larsen, Jan P" sort="Larsen, Jan P" uniqKey="Larsen J" first="Jan P." last="Larsen">Jan P. Larsen</name>
</noRegion>
</country>
<country name="Slovénie"><noRegion><name sortKey="Pirtosek, Zvezdan" sort="Pirtosek, Zvezdan" uniqKey="Pirtosek Z" first="Zvezdan" last="Pirtosek">Zvezdan Pirtosek</name>
</noRegion>
</country>
<country name="République tchèque"><region name="Bohême centrale"><name sortKey="R Uzizka, Evzen" sort="R Uzizka, Evzen" uniqKey="R Uzizka E" first="Evzen" last="R Užižka">Evzen R Užižka</name>
</region>
<name sortKey="Jech, Robert" sort="Jech, Robert" uniqKey="Jech R" first="Robert" last="Jech">Robert Jech</name>
</country>
<country name="Pologne"><noRegion><name sortKey="Slawek, Jaroslaw" sort="Slawek, Jaroslaw" uniqKey="Slawek J" first="Jaroslaw" last="Sławek">Jaroslaw Sławek</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003747 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003747 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:E157C5AC16E873F5B278A64D8217108550AB8135
   |texte=   Retrospective evaluation of the dose of dysport and BOTOX in the management of cervical dystonia and blepharospasm: The REAL DOSE study
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Retrospective evaluation of the dose of dysport and BOTOX in the management of cervical dystonia and blepharospasm: The REAL DOSE study

Retrospective evaluation of the dose of dysport and BOTOX in the management of cervical dystonia and blepharospasm: The REAL DOSE study

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.